Construction and evaluation of a multistage Mycobacterium tuberculosis subunit vaccine candidate Mtb10.4–HspX

Vaccine ◽  
2011 ◽  
Vol 29 (51) ◽  
pp. 9451-9458 ◽  
Author(s):  
Hongxia Niu ◽  
Lina Hu ◽  
Qing Li ◽  
Zejiao Da ◽  
Bingxiang Wang ◽  
...  
Keyword(s):  
Mycobacterium Tuberculosis ◽  
Subunit Vaccine ◽  
Vaccine Candidate

scholarly journals Multi-Stage Tuberculosis Subunit Vaccine Candidate LT69 Provides High Protection against Mycobacterium tuberculosis Infection in Mice

PLoS ONE ◽  
2015 ◽  
Vol 10 (6) ◽  
pp. e0130641 ◽  
Author(s):  
Hongxia Niu ◽  
Jinxiu Peng ◽  
Chunxiang Bai ◽  
Xun Liu ◽  
Lina Hu ◽  
...  
Keyword(s):  
Mycobacterium Tuberculosis ◽  
Subunit Vaccine ◽  
Vaccine Candidate ◽  
Tuberculosis Infection ◽  
Mycobacterium Tuberculosis Infection ◽  
Multi Stage

Corrigendum to “Protection of mice from Mycobacterium tuberculosis by ID87/GLA-SE, a novel tuberculosis subunit vaccine candidate” [Vaccine 29 (2011) 7842–7848]

Vaccine ◽  
2012 ◽  
Vol 31 (1) ◽  
pp. 278
Author(s):  
Hillarie Plessner Windish ◽  
Malcolm S. Duthie ◽  
Ayesha Misquith ◽  
Greg Ireton ◽  
Elyse Lucas ◽  
...  
Keyword(s):  
Mycobacterium Tuberculosis ◽  
Subunit Vaccine ◽  
Vaccine Candidate ◽  
Candidate Vaccine

scholarly journals Protection of mice from Mycobacterium tuberculosis by ID87/GLA-SE, a novel tuberculosis subunit vaccine candidate

Vaccine ◽  
2011 ◽  
Vol 29 (44) ◽  
pp. 7842-7848 ◽  
Author(s):  
Hillarie Plessner Windish ◽  
Malcolm S. Duthie ◽  
Greg Ireton ◽  
Elyse Lucas ◽  
John D. Laurance ◽  
...  
Keyword(s):  
Mycobacterium Tuberculosis ◽  
Subunit Vaccine ◽  
Vaccine Candidate

Construction and immunogenicity of a new Fc-based subunit vaccine candidate against Mycobacterium tuberculosis

2016 ◽  
Vol 43 (9) ◽  
pp. 911-922 ◽  
Author(s):  
Abdollah Kebriaei ◽  
Mohammad Derakhshan ◽  
Zahra Meshkat ◽  
Mohammad Reza Akbari Eidgahi ◽  
Seyed Abdolrahim Rezaee ◽  
...  
Keyword(s):  
Mycobacterium Tuberculosis ◽  
Subunit Vaccine ◽  
Vaccine Candidate

scholarly journals Mucosal Influenza Vector Vaccine Carrying TB10.4 and HspX Antigens Provides Protection against Mycobacterium tuberculosis in Mice and Guinea Pigs

Vaccines ◽  
2021 ◽  
Vol 9 (4) ◽  
pp. 394
Author(s):  
Mariia Sergeeva ◽  
Ekaterina Romanovskaya-Romanko ◽  
Natalia Zabolotnyh ◽  
Anastasia Pulkina ◽  
Kirill Vasilyev ◽  
...  
Keyword(s):  
Mycobacterium Tuberculosis ◽  
Vaccine Candidate ◽  
Cell Immune Response ◽  
Lung Pathology ◽  
Ns1 Protein ◽  
Reading Frame ◽  
Intranasal Immunization ◽  
Vector Vaccine ◽  
Boost Immunization ◽  
New Strategies

New strategies providing protection against tuberculosis (TB) are still pending. The airborne nature of Mycobacterium tuberculosis (M.tb) infection assumes that the mucosal delivery of the TB vaccine could be a more promising strategy than the systemic route of immunization. We developed a mucosal TB vaccine candidate based on recombinant attenuated influenza vector (Flu/THSP) co-expressing truncated NS1 protein NS1(1–124) and a full-length TB10.4 and HspX proteins of M.tb within an NS1 protein open reading frame. The Flu/THSP vector was safe and stimulated a systemic TB-specific CD4+ and CD8+ T-cell immune response after intranasal immunization in mice. Double intranasal immunization with the Flu/THSP vector induced protection against two virulent M.tb strains equal to the effect of BCG subcutaneous injection in mice. In a guinea pig TB model, one intranasal immunization with Flu/THSP improved protection against M.tb when tested as a vaccine candidate for boosting BCG-primed immunity. Importantly, enhanced protection provided by a heterologous BCG-prime → Flu/THSP vector boost immunization scheme was associated with a significantly reduced lung and spleen bacterial burden (mean decrease of 0.77 lg CFU and 0.72 lg CFU, respectively) and improved lung pathology 8.5 weeks post-infection with virulent M.tb strain H37Rv.

scholarly journals Evaluation of a subunit vaccine candidate (Biotech Vac Cox) against Eimeria spp. in broiler chickens

2021 ◽  
pp. 101329
Author(s):  
Emanuel Gumina ◽  
Jeffrey W. Hall ◽  
Bruno Vecchi ◽  
Xochitl Hernandez-Velasco ◽  
Brett Lumpkins ◽  
...  
Keyword(s):  
Broiler Chickens ◽  
Subunit Vaccine ◽  
Vaccine Candidate ◽  
Eimeria Spp ◽  
A Subunit

scholarly journals A Phase 1/2 Clinical Trial Evaluating Safety and Immunogenicity of a Varicella Zoster Glycoprotein E Subunit Vaccine Candidate in Young and Older Adults

2012 ◽  
Vol 206 (8) ◽  
pp. 1280-1290 ◽  
Author(s):  
Isabel Leroux-Roels ◽  
Geert Leroux-Roels ◽  
Frédéric Clement ◽  
Pierre Vandepapelière ◽  
Ventzislav Vassilev ◽  
...  
Keyword(s):  
Older Adults ◽  
Clinical Trial ◽  
Subunit Vaccine ◽  
Vaccine Candidate ◽  
Phase 1 ◽  
Glycoprotein E ◽  
Varicella Zoster

scholarly journals Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcRγ–Syk–Card9–dependent innate immune activation

2009 ◽  
Vol 206 (1) ◽  
pp. 89-97 ◽  
Author(s):  
Kerstin Werninghaus ◽  
Anna Babiak ◽  
Olaf Groß ◽  
Christoph Hölscher ◽  
Harald Dietrich ◽  
...  
Keyword(s):  
Mycobacterium Tuberculosis ◽  
Subunit Vaccine ◽  
Vaccine Development ◽  
Adaptor Protein ◽  
Synthetic Analogue ◽  
Dependent Manner ◽  
Immunostimulatory Activity ◽  
Adjuvant Activity ◽  
Cord Factor

Novel vaccination strategies against Mycobacterium tuberculosis (MTB) are urgently needed. The use of recombinant MTB antigens as subunit vaccines is a promising approach, but requires adjuvants that activate antigen-presenting cells (APCs) for elicitation of protective immunity. The mycobacterial cord factor Trehalose-6,6-dimycolate (TDM) and its synthetic analogue Trehalose-6,6-dibehenate (TDB) are effective adjuvants in combination with MTB subunit vaccine candidates in mice. However, it is unknown which signaling pathways they engage in APCs and how these pathways are coupled to the adaptive immune response. Here, we demonstrate that these glycolipids activate macrophages and dendritic cells (DCs) via Syk–Card9–Bcl10–Malt1 signaling to induce a specific innate activation program distinct from the response to Toll-like receptor (TLR) ligands. APC activation by TDB and TDM was independent of the C-type lectin receptor Dectin-1, but required the immunoreceptor tyrosine-based activation motif–bearing adaptor protein Fc receptor γ chain (FcRγ). In vivo, TDB and TDM adjuvant activity induced robust combined T helper (Th)-1 and Th-17 T cell responses to a MTB subunit vaccine and partial protection against MTB challenge in a Card9-dependent manner. These data provide a molecular basis for the immunostimulatory activity of TDB and TDM and identify the Syk–Card9 pathway as a rational target for vaccine development against tuberculosis.

scholarly journals A Mycobacterium tuberculosis-specific subunit vaccine that provides synergistic immunity upon co-administration with Bacillus Calmette-Guérin

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Joshua S. Woodworth ◽  
Helena Strand Clemmensen ◽  
Hannah Battey ◽  
Karin Dijkman ◽  
Thomas Lindenstrøm ◽  
...  
Keyword(s):  
Mycobacterium Tuberculosis ◽  
Subunit Vaccine ◽  
Clinical Results ◽  
Cross Reactivity ◽  
Bacillus Calmette Guerin ◽  
Adaptive Responses ◽  
Vaccine Strategy ◽  
Subunit Vaccines ◽  
Protective Antigens

AbstractGiven the encouraging clinical results of both candidate subunit vaccines and revaccination with Bacillus Calmette-Guérin (BCG) against tuberculosis (TB), there is support for combining BCG and subunit vaccination for increased efficacy. BCG and Mycobacterium tuberculosis (Mtb) share ~98% of their genome and current subunit vaccines are almost exclusively designed as BCG boosters. The goal of this study is to design a TB subunit vaccine composed of antigens not shared with BCG and explore the advantages of this design in a BCG + subunit co-administration vaccine strategy. Eight protective antigens are selected to create an Mtb-specific subunit vaccine, named H107. Whereas traditional vaccines containing BCG-shared antigens exhibit in vivo cross-reactivity to BCG, H107 shows no cross-reactivity and does not inhibit BCG colonization. Instead, co-administering H107 with BCG leads to increased adaptive responses against both H107 and BCG. Importantly, rather than expanding BCG-primed T cells, H107 broadens the overall vaccine repertoire with new T cell clones and introduces ‘adjuvant-imprinted’ qualities including Th17 responses and less-differentiated Th1 cells. Collectively, these features of H107 are associated with a substantial increase in long-term protection.

Sign in / Sign up

Export Citation Format

Share Document